Rand Sutherland
Chief Executive Officer of Upstream Bio, leading development of verekitug (a TSLP receptor antagonist) with expertise in clinical development and commercialization strategy for respiratory and type 2 inflammatory diseases.
Best podcasts with Rand Sutherland
Ranked by the Snipd community
8 snips
Feb 11, 2026 • 13min
Upstream Bio's CEO Rand Sutherland discusses today's severe asthma data for verekitug, a TSLP receptor antagonist
Rand Sutherland, CEO of Upstream Bio and developer of verekitug, a TSLP receptor antagonist for respiratory and type 2 inflammatory disease. He walks through top-line severe asthma data across multiple doses. He explains the striking high-dose Q12-week results, dosing-frequency advantages versus monthly competitors, and plans for phase 3, regulators, and additional CRS and COPD programs.
